Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies
Endocrine Oncology · 01.01.2025 · 5 (1)
DOI: 10.1530/eo-25-0051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 10.11.2025. Verfasst von Po Hien Ear und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Neuroendocrine neoplasms (NENs) are rare cancers originating in various organs and are further classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Commonly used drugs such as proton pump inhibitors can promote gastric NEN growth. Nowadays, incretin mimetic drugs such as glucagon-like peptide 1 receptor (GLP-1R) agonists have gained extensive popularity for the treatment of diabetes and obesity. These drugs target GLP-1R, and their use in neuroendocrine cancer patients with medullary thyroid carcinoma (thyroid NET) or multiple endocrine neoplasia syndrome type 2 is deemed contraindicated. Previous studies investigated GLP-1R expression in small subsets of NENs. Here, we assessed GLP-1R expression by immunohistochemistry in a large collection of 576 patient NENs from 13 sites of origin. We identified that 7% of NENs stained positive for GLP-1R. They were from five NEN types: duodenal NETs (dNETs), gastric NETs, pancreatic NETs, pheochromocytomas, and lung NETs. We then validated the dNET spheroids for response to an incretin mimetic drug and found activation of the MAPK pathway and growth. While GLP-1R agonists are contraindicated in patients with thyroid NETs, none of our 29 thyroid NETs expressed GLP-1R. Hence, in contrast to rodent studies, GLP-1R agonists may have little effect on human thyroid NETs since they do not express the receptor. Interestingly, ileal NETs also showed no expression of GLP-1R. More preclinical research examining potential oncogenic effects of incretin mimetics on the five subtypes of GLP-1R-positive NENs is needed to better understand their safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pathology University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
- Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
- Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
ORCID-Profile: Po Hien Ear
Förderung
- NCI NIH HHS
Zitieren
APA
Ear, P. H., Hueser, S. A., Townsend, R. E., Maxwell, J. E., Abusada, E., Chan, C. H. F., Quelle, D. E., Dillon, J. S., Howe, J. R., & Bellizzi, A. M. (2025). Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies. Endocrine Oncology, 5(1). https://doi.org/10.1530/eo-25-0051
Vancouver
Ear PH, Hueser SA, Townsend RE, Maxwell JE, Abusada E, Chan CHF, et al. Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies. Endocrine Oncology. 2025;5(1). doi:10.1530/eo-25-0051
BibTeX
@article{Ear2025,
author = {Ear, Po Hien and Hueser, Sophia A and Townsend, Reese E and Maxwell, Jessica E and Abusada, Ellen and Chan, Carlos H F and Quelle, Dawn E and Dillon, Joseph S and Howe, James R and Bellizzi, Andrew M},
title = {Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies},
journal = {Endocrine Oncology},
year = {2025},
volume = {5},
number = {1},
doi = {10.1530/eo-25-0051}
}
EUVIMED